Mucoadhesive microspheres based formulation development of ziprasidone hydrochloride for nasal delivery

Yogita Sahu¹, Sourabh Jain*², Karunakar Shukla²

¹Central India Institute of Pharmacy, Indore Bypass Rd, Manglaya Sadak, Indore, MP 453771, India
²College of Pharmacy, Dr. A. P. J. Abdul Kalam University, Village, Post, Indore Bypass Rd, Arandia, Jhalariya, Madhya Pradesh 452016, India

ABSTRACT

The aim of the present work is to develop mucoadhesive microspheres of Ziprasidone hydrochloride for nasal delivery with the aim to enhance the residence time and improve therapeutic efficacy. Mucoadhesive drug delivery systems are those that provide intimate contact of the drug with the mucosa for an extended period of time. In our present work, mucoadhesive chitosan microspheres were prepared by emulsification method using liquid paraffin as external phase. Ten different formulations were developed. Results show that as the concentration of polymer increases it affects the particle size, production yield, encapsulation efficiency, swelling index, in-vitro mucoadhesion and in-vitro drug release of mucoadhesive microspheres. The in vitro mucoadhesion of microspheres was investigated using freshly isolated goat nasal mucosa. The mucoadhesions for M0, M1, M2, and M9 was tested. The mucoadhesion property was satisfactory. The M2 exhibited lowest mucoadhesion of 68.9%, and M0 displayed highest mucoadhesion of 87.5%. The In Vitro release studies it revealed that 84.1% of drug release from formulation M1 at 7hrs. The 50% of the drug was released from the formulation M2 and 70.67% from formulation M9. This formulations were further used for SEM for particles size analysis, mucoadhesion test and in-vitro drug release. The In-vitro % drug release data suggest that the maximum and sustained drug release was obtained for formulation M1. The present study showed that Ziprasidone hydrochloride chitosan microspheres can deliver intranasally which can improve the therapeutic outcome for the Epileptic seizure.

Keywords: Ziprasidone hydrochloride, Mucoadhesive microspheres, Nasal drug delivery, Drug Entrapment efficiency.

INTRODUCTION

Mucoadhesive drug delivery systems are those systems that utilize bioadhesion of certain polymers that become adhesive on hydration. Thus, they can be used for targeting a drug to a particular region of the body for extended period of time. The mucus membrane lines a number of regions of the body including the gastrointestinal tract (GIT), urogenital tract, airways, ear, nose, and eye. These are strong sites for attachment of any bioadhesive system, and hence the mucoadhesive drug delivery systems include buccal, oral, vaginal, rectal, nasal, and ocular delivery systems. The nasal mucosa has far higher permeability than other mucosal surfaces including the various regions of the GIT, buccal, and vaginal cavities. Recently, mucoadhesive dosage forms have received substantial attention to improve the bioavailability of drug by prolonging the residence time and controlling drug release characteristics. Thus, mucoadhesion may lead to the solution of bioavailability problems resulting from a too-short stay of the pharmaceutical dosage form at the absorption site of the active ingredients. Faster absorption and easy administration through nasal cavity make the nasal drug delivery a promising route for administration of drugs. It appears to be an ideal alternative to the parenterals for administrating drugs intended for systemic effects in view of the rich vascularization of nasal membrane and the ease of intranasal administration. The delivery of drug by this route has distinct advantages of protecting the drug from the hepatic first-pass elimination, gut wall metabolism, and destruction in GIT, and it also offers excellent controlled release of drug and better systemic therapeutic response. Moreover, there exists a rich vasculature and a highly permeable structure in the nasal membranes for absorption. Ziprasidone hydrochloride was the fifth a typical antipsychotic for the treatment of schizophrenia and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Chitosan is a natural polymer that has mucoadhesive properties because of its positive charges at neutral pH, which enable an ionic interaction with the negative charges of sialic acid residues.
on the mucus. This highly mucoadhesive characteristics of chitosan provide a longer contact period for drug transport through nasal mucosa and prevents the clearance of the formulation via mucociliary clearance mechanism. Therefore, chitosan microspheres have been extensively evaluated as a drug delivery system. The objective of the present study is to formulate and evaluate mucoadhesive microspheres of Ziprasidone hydrochloride that will increase residence time in the nasal cavity and at the same time increase the local of absorption of drug and reducing systemic side effects and also to develop unique controlled delivery system for patients suffering from allergy and rhinitis. The microspheres were prepared by emulsion cross linking method in different ratio by using mucoadhesive polymer, chitosan.

MATERIAL AND METHODS

Material

Ziprasidone hydrochloride was obtained as a gift sample from CADILA Pharmaceutical Pvt. Ltd., Ahmedabad, Gujarat. All the chemicals and ingredients were of analytical grade and supplied from authentic suppliers i.e. Chitosan (Chemika Biochemika Reagents, India), n-Hexane (Merck, Germany) Sodium Lauryl Sulphate (SLS), liquid paraffin (Kaslival Bros, Indore, India), Gluteraldehyde (GA) (25% Aqueous Solution) (Spectrochem Pvt. Ltd, Mumbai, India), (Loba Chemie Pvt Ltd Mumbai, India).

Methods

Identification and characterization of API and polymer

Assay of ziprasidone hydrochloride by UV spectrophotometry

Ziprasidone Hydrochloride assay was performed by using UV spectrophotometric method mentioned in some articles (UV spectrophotometer, Shimadzu, Japan) and observations were compared with standards. When examinations were performed sample was scanned in the range of 300 – 500 nm maximum absorbance was observed in the range of 509 nm to 521 nm with the solvent methanol as mention in the article.

FTIR spectroscopy

Fourier transform Infrared absorption spectrophotometry (FT-IR) was performed and spectrum was compared with reference spectrum of Ziprasidone Hydrochloride and chitosan.

Melting point determination

Melting points of Ziprasidone Hydrochloride and Chitosan were determined with the help of melting point apparatus and compared with standards.

DSC analysis

Differential scanning calorimetric (DSC) study was carried out to confirm the thermal behavior of Ziprasidone Hydrochloride and chitosan.

Preparation of blank chitosan microspheres by emulsification

Chitosan microspheres were prepared by simple w/o emulsification-cross linking process by using liquid paraffin (heavy and light, 1:1). The hardened microspheres were separated by filtration and washing of microspheres were done for several times with hexane to remove oil. Finally, microspheres were washed with distilled water to remove unreacted GA. Solution was added slowly to liquid paraffin (heavy and light, 1:1) containing 0.2% (w/v) of SLS as stabilizing agent under constant stirring at the speed of 2000 rpm for 15 min using a high speed mechanical stirrer. The microspheres were air dried for 24 hrs and then stored in vacuum desiccator until further use.

Preparation of ziprasidone hydrochloride loaded chitosan microspheres

Ziprasidone Hydrochloride loaded chitosan microspheres were prepared by simple w/o emulsification-cross linking process using liquid paraffin (heavy and light, 1:1) as external phase. At first, Ziprasidone Hydrochloride was dissolved in 2ml of acetone and sonicated till a clear solution is obtained. Chitosan was dissolved in 2% aqueous acetic acid solution by continuously stirring and then solution of chitosan was added in the drug solution with continuous stirring at constant speed until a homogeneous solution was obtained. This solution was added slowly to liquid paraffin (heavy and light, 1:1) containing 0.2% (w/v) of SLS as stabilizing agent under constant stirring at a speed 1800 rpm for 15 min using a high speed mechanical stirrer. To this w/o emulsion, GA was added slowly and stirring was continued for 2 hrs. The hardened microspheres were separated by vacuum filtration and washed several times with hexane to remove oily part. Finally, microspheres were washed with distilled water to remove unreacted GA. The microspheres were air dried for 24 h and then stored in desiccator until further use. To evaluate the effect of different formulation and process variables on particle size, encapsulation efficiency, drug loading etc., various batch of formulations were prepared by varying one parameter and keeping the others constant as given in Table 1.

Table 1: composition of Ziprasidone hydrochloride mucoadhesive microspheres

| F. No. | Drug : Polymer (Ratio) | Aqueous : Oil (Ratio) | GA (ml) | SLS (%) | Stirring Rate (rpm) | Cross Linking Time (Hrs) |
|-------|------------------------|----------------------|---------|---------|---------------------|-------------------------|
| M0    | 0:10                   | 10:100               | 2       | 0.2     | 1800                | 2                       |
| M1    | 1:9                    | 10:100               | 2       | 0.2     | 1800                | 2                       |
| M2    | 2:8                    | 10:100               | 2       | 0.2     | 1800                | 2                       |
| M3    | 3:7                    | 10:100               | 2       | 0.2     | 1800                | 2                       |
| M4    | 1:9                    | 20:100               | 2       | 0.2     | 1800                | 2                       |
| M5    | 1:9                    | 10:100               | 2       | 0.2     | 1200                | 2                       |
| M6    | 1:9                    | 10:100               | 2       | 0.2     | 1500                | 2                       |
| M7    | 1:9                    | 10:100               | 2       | 0.1     | 1800                | 2                       |
| M8    | 1:9                    | 10:100               | 2       | 0.2     | 1800                | 3                       |
| M9    | 1:9                    | 10:100               | 2       | 0.2     | 1800                | 3                       |
**Characterization of microspheres**

**Production yield (%)**

Production yield of microspheres of various batches were calculated using the weight of final product after drying with respect to the initial total weight of the drug and polymer used for preparation of microspheres and % production yields were calculated by formula \[ \text{Production yield} = \frac{W_d - W_0}{W_0} \times 100 \]

Where \( O_\text{C} \) = degree of swelling

\( W_0 \) = weight of microspheres before swelling and

\( W_s \) = weight of microspheres after swelling.

**Degree of swelling**

The degree of swelling of microspheres was investigated by using the degree of swelling in the phosphate buffer solution of pH 6.4. Accurately weighed amount of microspheres (10 mg) was immersed in little excess of PBS pH 6.4 for 24 hrs followed by washing. The degree of swelling was calculated using following method: A known weight (50mg) of microspheres were placed in a glass vial containing 10mL phosphate buffer of pH 6.8 and maintained at 37 ± 0.5°C with gentle shaking for 24 h. After that, microspheres were removed, blotted with filter paper and subsequently the weight of swollen microspheres (Wsw) was measured.

The swelling ratio (SR) was calculated according to the following equation

\[ \text{SR} = \frac{W_s - W_0}{W_0} \]

**In vitro mucoadhesion studies**

Mucoadhesion of microspheres was assessed by using the method reported with little modification. The in vitro mucoadhesion of microspheres was investigated by using freshly isolated goat nasal mucosa. In brief, nasal mucosal tissues were carefully removed from the nasal cavity of goat, which was obtained from the local slaughter house within 60 minutes of slaughtering the animal. The tissues were cut into the size of 1×1 cm and were mounted onto the glass slide and accurately weighed microspheres (10 mg) were sprinkled on the mucosa. This glass slide was kept in desiccator for 15 min to allow the polymer to interact with the mucosal surface and finally placed in the cell that was attached to the outer assembly at an angle of 45°. Phosphate buffer solution pH 6.4, previously warmed to 37 ± 0.5°C was circulated all over the microspheres and membrane at the rate of 1 ml/min. Washings were collected at different time intervals and microspheres were collected by centrifugation followed by drying at 50°C. The weight of washed out microspheres was determined and percent mucoadhesion was calculated by standard formula.

**External morphological evaluation**

**Optical microscopy**

All batches of microspheres were studied for shape and size by optical microscopy (Olympus Microscope, Olympus Optical Co. Ltd., Japan). The samples were studied in the form of dispersion in paraffin oil.

**RESULT AND DISCUSSION**

**Identification and characterization of API and polymer**

**Assay of ziprasidone hydrochloride by UV spectrophotometry**

The Ziprasidone Hydrochloride was identified by UV spectroscopy method. The Ziprasidone Hydrochloride exhibited maximum absorption at 521 nm. After scanning the \( \lambda_{\text{max}} \) of the Ziprasidone Hydrochloride with methanol it matches with that of the standard \( \lambda_{\text{max}} \) given in the articles (521nm). This wavelength was considered as \( \lambda_{\text{max}} \) for samples and all the observations by UV spectrophotometer to calculate the amount of drug was taken at this wavelength. The Calibration curve of Ziprasidone Hydrochloride is shown in Fig.1.

**FTIR spectroscopy**

The spectra of FTIR (Fig.2) and its description and interpretation in the below tables indicate that the sample used was Ziprasidone hydrochloride.
DSC analysis

From Figure 3 it has been observed that the drug endothermic peak disappeared. It has been reported that when the drug does not show its endothermic peak in the microsphere, it is said to be in the amorphous state or disordered crystalline phase as a molecular dispersion in polymeric matrix. Hence, it could be concluded that the drug was present in the amorphous or solid phase and may have been homogeneously dispersed in the microsphere.

Characterization and evaluation of microspheres

Ten formulation of ziprasidone hydrochloride microspheres were prepared to optimize the formula. The effect of drug-polymer ratio, aqueous-oil ratio, quantity of dispersing agent, GA and stirring rate of stirrer on particle geometry of microsphere has been studied.

Optical microscopy

Microspheres were characterized in terms of sphericity and clumping of microspheres by optical microscopy. Optical microscopy of drug loaded microspheres depicted irregular geometry in some batches due to which those batches fail to achieve better encapsulation. Here we are discussing geometry of all the batches and observed almost spherical geometry with few aggregates in some formulations. Formulations M0 and M1 shows uniform spherical shapes with no aggregation of spherical. On the other way formulation M2 shows non-uniform size and shapes of particles with no aggregation. Formulation M3 shows irregular and degraded particles with no aggregation. Formulation M4 represents aggregated and clumsy particles and on the other hand formulation M5 shows dense aggregation of particles. Formulations M6 and M7 shows clumping of particles with irregular geometry. Formulation M8 shows lumps formation and at last formulation M9 shows spherical shaped microspheres with no aggregation. The findings of optical microscopy suggest that the particle of microspheres of M0, M1 and M9 were satisfactory.

Figure 2: FT-IR Spectra of ziprasidone hydrochloride, chitosan and formulation

Figure 3: DSC thermogram of ziprasidone hydrochloride, chitosan and formulation

Figure 4: Microscopical images of satisfactory batches (M0, M1, M9)
Production yield (%)

It was recorded that as concentration of polymer increases production yield decreases, since increase in polymeric concentration make solution more viscous this was difficult to pour and get stucked on the wall of the beaker. The % production yield of microspheres was found to be maximum for M3 (74.59%) having lowest amount of polymer. Lowest % yield was of formulation M4 (51.56%). Stirring rate also affects production yield Table 2.

Table 2: Obtained production yield of all the formulations

| Formulation No. | Practical mass (mg) | Theoretical mass (mg) | Production yield (%) |
|-----------------|---------------------|-----------------------|---------------------|
| M0              | 60.24               | 100                   | 60.24               |
| M1              | 63.12               | 100                   | 63.12               |
| M2              | 71.89               | 100                   | 71.89               |
| M3              | 74.11               | 100                   | 74.11               |
| M4              | 51.56               | 100                   | 51.56               |
| M5              | 54.03               | 100                   | 54.03               |
| M6              | 58.43               | 100                   | 58.43               |
| M7              | 50.01               | 100                   | 50.01               |
| M8              | 61.78               | 100                   | 61.78               |
| M9              | 64.21               | 100                   | 64.21               |

Entrapment efficiency (%)

The entrapment efficiencies of drug were recorded in the range of 48.05% to 79% for M1 to M9. The M8 revealed lowest entrapment efficiency of drug i.e. 48.09%, while M1 displayed 79% highest drug entrapment efficiency when compared to other formulations. From results it has been observed that on increasing the polymer ratio the drug entrapment efficiency increases. This might be due to higher concentration of polymer make solution highly viscous which increases the drug entrapment. Meanwhile increasing the stirring rate also enhances the drug entrapment in microspheres because increasing the stirring rate decreases the particle size of microsphere and surface area of microsphere enhanced, this intensifies the drug permeability inside the microspheres. It is another reason that can which increases the drug entrapment efficiency in microspheres Table 3.

Table 3: Entrapment efficiency of microspheres of drug load formulations

| Formulations | Entrapment Efficiency (%) |
|--------------|---------------------------|
| M1           | 79.54                     |
| M2           | 62.87                     |
| M3           | 56.18                     |
| M4           | 71.23                     |
| M5           | 71.65                     |
| M6           | 50.34                     |
| M7           | 52.76                     |
| M8           | 48.09                     |
| M9           | 70.65                     |

Degree of swelling index

The degree of swelling was ranged from 0.36 to 1.66% for formulations M0 to M9. The lowest degree of swelling was observed in M3 (0.36%) and the highest degree of swelling was noticed in M0 (1.66%) Table 4.

Table 4: Degree of swelling of microspheres

| Formulations | Weight of microspheres before swelling | Weight of microspheres after swelling | Degree of Swelling (%) |
|--------------|----------------------------------------|--------------------------------------|------------------------|
| M0           | 60.24                                  | 61.65                                | 1.66                   |
| M1           | 63.12                                  | 63.96                                | 1.33                   |
| M2           | 71.89                                  | 72.19                                | 0.41                   |
| M3           | 74.11                                  | 75.88                                | 0.36                   |
| M4           | 51.56                                  | 51.86                                | 0.58                   |
| M5           | 54.03                                  | 54.24                                | 0.38                   |
| M6           | 58.43                                  | 58.98                                | 0.941                  |
| M7           | 60.01                                  | 60.59                                | 0.966                  |
| M8           | 51.78                                  | 51.95                                | 0.57                   |
| M9           | 64.21                                  | 65.01                                | 1.24                   |
The results of the studies revealed that, swelling ratio of the microspheres increased with increasing the ratio of the polymer which could be due to more amount of polymer present in the microspheres that may be responsible for higher swelling. Swelling ratios were also increased with reduced particle size of the microspheres. This could be probably due to the reason that when the particle size is reduced, more surface area will be exposed to the swelling medium and consequently leads to the higher swelling of the microspheres. Swelling ratios of the microspheres reduced when the extent of cross-linking was increased. This could be due to fact that, higher concentration of gluteraldehyde which dense the cross-linking of polymeric chains thereby limiting the penetration of the medium in to the polymeric matrix thereby reducing the swelling ability of the microspheres. On the bases of above evaluations only four formulations M0, M1, M2 and M9 were selected for further tests.

| Formulations | Weight of microspheres applied (mg) | Weight of microspheres leached out (mg) | Mucoadhesion (%) |
|--------------|------------------------------------|----------------------------------------|------------------|
| M0           | 10                                 | 1.25                                   | 87.5             |
| M1           | 10                                 | 1.52                                   | 84.8             |
| M2           | 10                                 | 3.11                                   | 68.9             |
| M9           | 10                                 | 2.59                                   | 74.1             |

From the results of mean particle size, production yield, entrapment efficiency, drug loading capacity, degree of swelling and mucoadhesion indicates that 3 formulations yield best microspheres over, all the parameters. Hence below mentioned 3 formulations were proceeds for further microscopic studies

Morphological characteristics of microsphere by SEM

The surface morphology of the drug loaded microsphere was investigated by scanning electron microscopy. Studies using SEM provided a better understanding of the morphological characteristics of the microspheres Fig. 5.

In vitro drug release studies

From the in vitro release studies it revealed that 84.1% of drug release from formulation M1 at 7hrs. The 50% of the drug was released from the formulation M2 and 70.67% from formulation M9. From above finding it has been noticed that on increasing the concentration of chitosan it decreased the drug release from microspheres. The high stirring rate, high concentration of chitosan and GA make the microsphere stiff. This hardness of microsphere decreases the rate of drug release from microspheres. Thus formulation M1 exhibited the sustained release of drug from microspheres in comparison to others Fig. 6.

Mucoadhesion test or In-vitro washes off test

On the basis of above evaluation only four formulations were selected for further tests. The mucoadhesion for M0, M1, M2, and M9 was tested. The Mucoadhesion property was satisfactory. The M2 exhibited lowest mucoadhesion of 68.9%, and M0 displayed highest mucoadhesion of 87.5%. The results showed that M0, M1, M9 had satisfactory mucoadhesive strength and could adequately adhere to nasal mucosa. Tensile studies performed with ziprasidone hydrochloride loaded microsphere showed that drug/polymer ratio significantly influenced the mucoadhesive properties of the microspheres. Hence high concentration of polymer imparts larger penetration with maximum adhesion thus, formulation M0, M1 and M9 satisfy the mucoadhesion on Table 5.
CONCLUSION
In the present study, an attempt was made to develop mucoadhesive nasal microspheres for systemic delivery of Ziprasidone Hydrochloride. The method of preparation used is Emulsification-cross linking process due to the nature of drug. Different formulation batches were evaluated for various parameters like production yield, entrapment efficiency, swelling index and particle geometry determination were found to get a better result for formulation M1, M2 and M9. This formulations were further used for SEM for particles size analysis, mucoadhesion test and in vitro drug release. The particle size of formulations was found to be satisfactory. The In vitro mucoadhesive study demonstrated that increase in polymer concentration, increases adherence of microspheres to mucous to a greater extent. The In vitro % drug release data suggest that the maximum and sustained drug release was obtained for formulation M1. In conclusion, the present study showed that Ziprasidone chitosan microspheres can deliver intranasally which can improve the therapeutic outcome for the Epileptic seizure.

REFERENCES
1. Nagai T, Machida Y Advances in drug delivery: mucosal adhesive dosage forms. Pharm Int, 1985; 6:196-200.
2. Kamath KR, Park K, Sugbrick J, Blaylen JC. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker, 1994.
3. Jimen J, Castanos MR, Zia H, Rhodes CT. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 1994; 19:143-154.
4. Illum L Chitosan and its use as a pharmaceutical excipients. Pharm Res 1998; 15:1326-1331.
5. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. Mucoadhesion of polymer coated liposomes to rat intestine in vitro. Chem Pharm Bull 1994; 42:195-4-1960.
6. Chien YW, Su KSE, Chang SF. Nasal Systemic Drug Delivery. New York: Marcel Dekker. 1989.
7. El-Say KM, BHelw AM, Ahmed OAA, Hosny KM, et al. Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs. Informa Healthcare, 2014; 1-9.
8. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 1992; 78:43-8.
9. Singla AK, Chawla M. Chitosan, Some pharmaceutical and biological aspects—an update. J Pharm Pharmacol 2001; 53:1047-67.
10. Soane RJ, Frier M, Perkins AC, Jones NS, et al. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999; 178:55-65.
11. Artursson P, Linbard M, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 1994; 11:1358-61.
12. Sinha VR, Singla AK, Wadhawan S, Kaushik R, et al. Chitosan microspheres as a potential carrier for drugs. Int J Pharm 2004; 274:1-33.
13. Hafner A, Filipovic-Greic J, Voinovich D, Jalsenjak I. Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine. Drug Dev Ind Pharm 2007; 33:427-36.
14. Asane GS, Nirmal SA, Rasal KB, Naik AA, et al. Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm 2000; 26:1246-66.
15. Borse MP, Mulung AY, UV Spectrophotometric estimation of ziprasidone in bulk and tablet dosage form. Der Pharm Lett, 2015; 7(5):272-275.
16. Varma MM, Begum R. Formulation, physicochemical evaluation, and dissolution studies of ziprasidone solid dispersions. Int J Pharm Sci Nanotech, 2012; 5(3):56-59.
17. Kumar RT, Unamaheswari S. FTIR, FTR and UV-Vis analysis of carbamazepine. Res J Pharm Biol Chem, 2011; 2(4):78-84.
18. Pajander J, Renonset AT, 0vandg M, Olsen MR, et al. Solid form change of Ziprasidon during hot melt processing. Thermochemica Acta 1995; 248:259-269.
19. Mitra A, Dey B. Chitosan microspheres in novel drug delivery systems. Indian J Pharm Sci. 2011; 73(4):355-366.
20. El Hamad MDA, Kellaway IW. Preparation and in vitro characterisation of mucoadhesive polymeric microspheres as intranasal delivery systems. Eur J Pharm Biopharm 1997; 44:53-60.
21. Lamprocht A, Torres HR, Schuler U, Lehr CM. Biodegradable microcarriers as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. J Contr Rel 2000; 69:445-454.
22. Dodda I, Shirahlgouda SP, Reddy BT, Kumar P, et al. Formulation and evaluation of brain-targeted nasal selegeline hydrochloride microspheres. Int J Pharm Biomed Res 2010; 20:123-156.
23. Gavini E, Hegge AB, Rassu G, Sanna V, et al nasal administration of ziprasidone using chitosan microspheres: in vitro/in vivo studies. Int J Pharm 2006; 307:9-15.
24. Charulatha R, Raja RK. Design and evaluation of Ziprasidone controlled release drug delivery system. Int J Pharm Tech Research, 2012; 2:23-45.